IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.345,78 +773,50 (+1,32%)
Voyager Therapeutics, Inc. (VYGR)
Después del cierre:
Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, MA 02421
United States
857 259 5340
https://www.voyagertherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 162
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, CEO & Director | 1,01M | N/A | 1958 |
| Ms. Robin Swartz | COO, Principal Financial & Accounting Officer and Acting Chief Business Officer | 661,98k | N/A | 1971 |
| Ms. Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer | 538,16k | N/A | 1971 |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder | N/A | N/A | N/A |
| Dr. Guangping Gao Ph.D. | Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
| Dr. Mark A. Kay M.D., Ph.D. | Founder | N/A | N/A | 1959 |
| Dr. Phillip D. Zamore Ph.D. | Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
| Mr. Todd Carter Ph.D. | Chief Scientific Officer | N/A | N/A | 1970 |
| Ms. Michelle Quinn Smith | Chief Human Resources Officer | N/A | N/A | N/A |
| Dr. Maria Lopez-Bresnahan M.B.A., M.D. | Senior Vice President of Translational Medicine & Clinical Development | N/A | N/A | N/A |
Descripción
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Voyager Therapeutics, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.
